托珠单抗治疗幼年特发性关节炎相关葡萄膜炎的研究进展

Abstract
Figure/Table
References (37)
Related Citation (15)

Download: PDF (623 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Guide

Abstract

Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA). The

commonest form of uveitis seen in JIA is recurrent chronic antetior uveitis with insidious onset and

complications, which can lead to ocular structural damage and vision loss. Interleukin-6 (IL-6) is a

pleiotropic cytokine and it can promote inflammatory response and immune regulation and other processes.

Tocilizumab, a humanized interleukin-6 receptor (IL-6R) monoclonal antibody, can competitively binds to

IL-6 receptor, which blocks the biological effects of endogenous IL-6. For JIA associated uveitis (JIAU)

patients who failed glucocorticoid, methotrexate and 2 monoclonal antibody TNFi at above-standard dose

and/or frequency, tocilizumab becomes a new treatment option for JIAU. This paper mainly summarizes

the mechanism, application and safety of tocilizumab in the treatment of JIAU in order to provide reference

for clinical decision-making.

Key words： juvenile idiopathic arthritis uveitis interleukin-6 tocilizumab treatment

Received: 02 November 2020

PACS:

Fund:

National Natural Science Foundation of China (81471575); Natural Science Foundation of

Gansu Province (17JR5RA225)

Corresponding Authors: Hong Lu, the First Clinical Medical College, Lanzhou University, Lanzhou 730000, China (Email: honglucmu@outlook.com)

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.cjoovs.com/EN/ OR https://www.cjoovs.com/EN/Y2022/V24/I2/150

[1]	Ravelli A, Consolaro A, Horneff G, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis, 2018, 77(6): 819-828.DOI: 10.1136/annrheumdis-2018-213030.
[2]	Sen E, Ramanan A. Juvenile idiopathic arthritis-associated uveitis. Clin Immunol, 2020, 211: 108322. DOI: 10.1016/j.clim.
20	19.108322.
[3]	孙利. 幼年特发性关节炎相关葡萄膜炎诊断和治疗. 中国实用儿科杂志, 2021, 36(1): 29-32. DOI: 10.19538/j.ek2021010607.
[4]	郑曰忠. 幼年特发性关节炎伴发葡萄膜炎.中华眼视光学与视觉科学杂志, 2015, 17(5): 306-310. DOI: 10.3760/cma.j.issn.1674-845X.2015.05.013
[5]	Hawkins MJ, Dick AD, Lee RJ, et al. Managing juvenile idiopathic arthritis-associated uveitis. Surv Ophthalmol, 2016,61(2): 197-210. DOI: 10.1016/j.survophthal.2015.10.005.
[6]	Constantin T, Foeldvari I, Anton J, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis, 2018, 77(8): 1107-1117. DOI: 10.1136/annrheumdis-2018-213131.
[7]	赵潺. 解读SHARE倡议和ACR/AF关于JIA相关葡萄膜炎的最新治疗共识.中国斜视与小儿眼科杂志, 2019, 27(3): 1-4.DOI: 10.3969/J.ISSN.1005-328X.2019.03.001.
[8]	Uciechowski P, Dempke WCM. Interleukin-6: a Masterplayer in the Cytokine Network. Oncology, 2020, 98(3): 131-137. DOI:
10	1159/000505099.
[9]	Mercer LK, Askling J, Raaschou P, et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with
	biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis, 2017, 76(2): 386-391. DOI:
10	1136/annrh eumdis-2016-209285.
[10]	Murakami M, Kamimura D, Hirano T. Pleiotropy and Specificity: insights from the Interleukin 6 Family of Cytokines.
	Immunity, 2019, 50(4): 812-831. DOI: 10.1016/j.immuni.2019.03.027.
[11]	Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation,immunity, and disease. Cold Spring Harb Perspect Biol, 2014,6(10): a016295. DOI: 10.1101/cshperspect.a016295.
[12]	许颖知, 卢弘, 陈巍, 等. 细胞因子在内毒素诱导的前葡萄膜炎小鼠房水和血清中的表达.眼科新进展, 2010, 30(4): 308-312. DOI: 10.13389/j.cn ki.rao.2010.04.006.
[13]	Zahir-Jouzdani F, Atyabi F, Mojtabavi N. Interleukin-6 participation in pathology of ocular diseases. Pathophysiology,2017, 24(3): 123-131. DOI: 10.1016/j.pathophys.2017.05.005.
[14]	Yoshimura T, Sonoda KH, Ohguro N, et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford), 2009, 48(4): 347-354. DOI:10.1093/rheumatology/ken489.
[15]	Wildschütz L, Ackermann D, Witten A, et al. Transcriptomic and proteomic analysis of iris tissue and aqueous humor in juvenile idiopathic arthritis-associated uveitis. J Autoimmun, 2019, 100:75-83. DOI: 10.1016/j.jaut.2019.03. 004.
[16]	Sijssens KM, Rijkers GT, Rothova A, et al. Cytokines,chemokines and soluble adhesion molecules in aqueous humor of children with uveitis. Exp Eye Res, 2007, 85(4): 443-449.DOI: 10.1016/j.exer.2007.06. 011.
[17]	Chen JL, Abiri P, Tsui E. Recent advances in the treatment of juvenile idiopathic arthritis-associated uveitis. Ther Adv Ophthalmol, 2021, 13: 1-14. DOI: 10.1177/ 2515841420984572.
[18]	Kalinina Ayuso V, Makhotkina N, van Tent-Hoeve M, et al.Pathogenesis of juvenile idiopathic arthritis associated uveitis:the known and unknown. Surv Ophthalmol, 2014, 59(5): 517-531. DOI: 10.1016/j.survophthal.2014.03.002.
[19]	Garbers C, Rose-John S. The balance between Treg and TH (17) cells: CD11b and interleukin-6. Eur J Immunol, 2017, 47(4):629-632. DOI: 10.1002/eji.201746988.
[20]	Knochelmann HM, Dwyer CJ, Bailey SR, et al. When worlds collide: Th17 and Treg cells in cancer and autoimmunity. Cell
	Mol Immunol, 2018, 15(5): 458-469. DOI: 10.1038/s41423-018-0004-4.
[21]	姜少杰, 梁士睿, 张雪芹, 等. IL-6/IL-6 受体轴及其靶向抑制剂研究进展. 细胞与分子免疫学杂志, 2019, 35(6): 569-574.DOI: 10.13423/j.cnki. cjcmi.008832.
[22]	Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res, 2014, 2(4): 288-294.DOI:10.1158/2326-6066.CIR-14-002 2.
[23]	Schett G. Physiological effects of modulating the interleukin-6 axis. Rheumatology (Oxford), 2018, 57(2): 43-50. DOI: 10.1093/rheumato-logy/kex513.
[24]	Scott LJ. Sarilumab: First Global Approval. Drugs, 2017, 77(6):705-712. DOI: 10.1007/s40265-017-0724-2.
[25]	Heissigerová J, Callanan D, de Smet MD, et al. Efficacy and Safety of Sarilumab for the Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU): the Phase 2 SATURN Study.Ophthalmology, 2019, 126(3): 428-437. DOI: 10.1016/j.ophtha.2018.09.044.
[26]	Tappeiner C, Heinz C, Ganser G, el al. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol, 2012, 39(6):1294-1295. DOI: 10.3899/jrheum.120010.
[27]	Calvo-Río V, Santos-Gómez M, Calvo I, et al. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-
	Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: a Multicenter Study of Twenty-Five Patients. Arthritis
	Rheumatol, 2017, 69(3): 668-675. DOI: 10.1002/art.39940.
[28]	Tappeiner C, Mesquida M, Adán A, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol, 2016, 43(12):2183-2188. DOI: 10.3899/ jrheum.160231.
[29]	Maleki A, Manhapra A, Asgari S, et al. Tocilizumab employment in the treatment of resistant juvenile idiopathic arthritis
	associated uveitis. Ocu Immunol Inflamm, 2021, 29(1): 14-20.DOI: 10.1080/0927 3948. 2020.1817501.
[30]	Dipasquale V, Atteritano M, Fresta J, et al. Tocilizumab for refractory uveitis associated with juvenile idiopathic arthritis: a
	report of two cases. J Clin Pharm Ther, 2019, 44(3): 482-485.DOI: 10.1111/ jcpt.12821.
[31]	Ramanan AV, Dick AD, Guly C, et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated
	uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial.Lancet Rheumatol, 2020, 2(3): e135-e141. DOI: 10.1016/S2665-
99	13(20)30008-4.
[32]	Mesquida M, Molins B, Llorenç V, et al. Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina, 2018, 38(7): 1361-1370. DOI: 10.1097/IAE. 0000000000001690.
[33]	Karkhur S, Hasanreisoglu M, Vigil E, et al. Interleukin-6 inhibition in the management of non-infectious uveitis and
	beyond. J Ophthalmic Inflamm Infect, 2019, 9(1): 17. DOI: 10.1186/s12348-019-0182-y.
[34]	Alfredo Adán, Moll-Udina A, Alba-Linero D, et al. Recent progress in the treatment of uveitic macular edema. Expert Rev Ophthalmol, 2019, 14(11): 1-10. DOI: 10.1080/17469899.2019.1644168.
[35]	Quesada-Masachs E, Caballero CM. Subcutaneous tocilizumab may be less effective than intravenous tocilizumab in the
	treatment of juvenile idiopathic arthritis-associated uveitis.J Rheumatol, 2017, 44(2): 260-261. DOI: 10.3899/jrheum.160908.
[36]	温晓娜, 刘文生, 孟舒献. 托珠单抗致不良反应的文献分析.现代药物与临床, 2020, 35(8): 1688-1693. DOI: 10.7501/j.issn.
16	74-5515.2020.08.041.
[37]	左玮, 刘容吉, 许秀丽, 等. 托珠单抗不良反应研究进展. 临床药物治疗杂志, 2020, 18(3): 16-20. DOI: 10.3969/j.issn.1672-3384.2020.03.004.